Effect of Evogliptin on the Progression of Aortic Valvular Calcification

In a 2024 study by Song et al., published in the *Journal of the American College of Cardiology*, researchers explored the effect of evogliptin, a DPP-4 inhibitor, on the progression of aortic stenosis (AS). The randomized controlled trial included 228 patients, divided into placebo, 5 mg, and 10 mg evogliptin groups. Over 96 weeks, aortic valve calcium volume (AVCV) was measured via computed tomography (CT), utilizing the AVIEW CAC software to calculate calcium scores. Additionally, active calcification was assessed using 18F-sodium fluoride PET at 48 weeks. The study found no significant difference in AVCV progression between evogliptin and placebo groups, but both evogliptin groups demonstrated a significant reduction in active calcification volume at 48 weeks. Although the trial did not show a reduction in AVCV, the suppression of calcification activity suggests that evogliptin may offer long-term benefits. Larger studies with extended follow-up are recommended to confirm its potential efficacy in slowing AS progression.